A randomized, prospective, open-label, controlled trial comparing the efficacy of omitting H2 antagonists versus famotidine in premedication protocol for prophylaxis of taxane hypersensitivity reactions A randomized, prospective, open-label, controlled trial comparing the efficacy of omitting H2 antagonists versus famotidine in premedication protocol for prophylaxis of taxane hypersensitivity reactions
Conditions
Interventions
Schedule of modified premedication without H2 antagonist protocol 1.Dexamethasone 20 mg intravenous 2.Ondansetron 8 mg oral 3.Diphenhydramine 50 mg oral 4.CPM 10 mg intravenous,Schedule of standard pr
modified premedication without H2 antagonist protocol,famotidine premedication protocol
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Cancer patients who received taxane chemotherapy regimen
Exclusion criteria
Exclusion criteria: 1.History of severe Hypersensitivity reactions from taxane regimen 2.Severe hepatic impairment (bilirubin >5xULN or AST/ALT >10xULN) 3. Patients with a history of severe hypersensitivity reactions to taxanes such as bronchospasm, hypotension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypersensitivity reactions every 3 week of six-cycle course of chemotherapy grading of Hypersensitivity reactions | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactChaichana Chantharakhit
Division of Medical Oncology, Department of Medicine, Buddhasothorn Hospital, Chachoengsao, Thailand
Outcome results
None listed